 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_id         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in the lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction [0m
[31mWARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with warfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint [0m
[31mwas a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was [0m[1;31m37[0m[31m months. The results for each endpoint [0m
[31mseparately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis of Separate Events % Risk Warfarin Placebo Reduction Event[0m
[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m
[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m
[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial infarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, [0m
[31mRe-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with warfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or [0m
[31mwarfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. WARFARIN: [0m
[31mclinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: WARIS II â€“ Distribution of Events According to Treatment Group[0m
[31mEvent Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a [0m[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m
[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b < [0m
[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral [0m
[31mhemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as compared with aspirin. c The rate ratio is for warfarin as compared [0m
[31mwith aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products, and inhibitors and inducers of [0m
[31mCYP2C9, 1A2, or 3A4. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium or increased risks for bleeding. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m General [0m
[31mInformation Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism [0m[1;31m([0m[31mimpaired[0m
[31mhemostasis, reduced clotting factor synthesis[0m[1;31m)[0m[31m, competitive antagonism [0m[1;31m([0m[31mvitamin K[0m[1;31m)[0m[31m, and alteration of the physiologic control loop for vitamin K metabolism [0m[1;31m([0m[31mhereditary resistance[0m[1;31m)[0m[31m. Pharmacokinetic [0m
[31mmechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. WARFARIN: drug_interactions: It is important to note that some[0m
[31mdrugs may interact by more than one mechanism. More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, [0m
[31mincluding drugs intended for short-term use [0m[1;31m([0m[31me.g., antibiotics, antifungals, corticosteroids[0m[1;31m)[0m[31m [0m[1;31m[[0m[31m see Boxed Warning [0m[1;31m][0m[31m. Consult the labeling of all concurrently used drugs to obtain further information [0m
[31mabout interactions with warfarin sodium or adverse reactions pertaining to bleeding. [0m[1;31m7.2[0m[31m CYP450 Interactions CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, [0m
[31m1A2, and 3A4. The more potent warfarin S -enantiomer is metabolized by CYP2C9 while the R -enantiomer is metabolized by CYP1A2 and 3A4. WARFARIN: drug_interactions: Inhibitors of CYP2C9, 1A2, and/or [0m
[31m3A4 have the potential to increase the effect [0m[1;31m([0m[31mincrease INR[0m[1;31m)[0m[31m of warfarin by increasing the exposure of warfarin. Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect [0m[1;31m([0m[31mdecrease[0m
[31mINR[0m[1;31m)[0m[31m of warfarin by decreasing the exposure of warfarin. Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table [0m[1;31m2[0m[31m ; however, this list should not be considered all-inclusive. [0m
[31mConsult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, [0m
[31mstopping, or changing dose of concomitant medications. WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of [0m
[31mCYP450 Interactions with Warfarin Enzyme Inhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, [0m
[31msulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, [0m
[31menoxacin, famotidine, fluvoxamine WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, [0m
[31mticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, [0m
[31matazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, [0m
[31mfosamprenav WARFARIN: drug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, [0m
[31mranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, [0m
[31mnafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN:[0m
[31mdrug_interactions: Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: [0m
[31mdrug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents[0m
[31maspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, [0m
[31mketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, [0m
[31mparoxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or [0m
[31mantifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic [0m
[31mor antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, [0m
[31mwell-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with [0m
[31mbotanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals [0m
[31mmay cause bleeding events when taken alone [0m[1;31m([0m[31me.g. WARFARIN: drug_interactions: garlic and Ginkgo biloba[0m[1;31m)[0m[31m and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be[0m
[31mexpected to be additive to the anticoagulant effects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium [0m[1;31m([0m[31me.g., co-enzyme Q [0m[1;31m10[0m[31m , St. Johnâ€™s wort, ginseng[0m[1;31m)[0m[31m. Some[0m
[31mbotanicals and foods can interact with warfarin sodium through CYP450 interactions [0m[1;31m([0m[31me.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. Johnâ€™s wort[0m[1;31m)[0m[31m. The amount of vitamin K in food may affect [0m
[31mtherapy with warfarin sodium. Advise patients taking warfarin sodium to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking warfarin sodium should avoid drastic [0m
[31mchanges in dietary habits, such as eating large amounts of green leafy vegetables.         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does WARFARIN increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_id         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in the lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction [0m
[31mWARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with warfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint [0m
[31mwas a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was [0m[1;31m37[0m[31m months. The results for each endpoint [0m
[31mseparately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis of Separate Events % Risk Warfarin Placebo Reduction Event[0m
[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m
[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m
[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial infarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, [0m
[31mRe-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with warfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or [0m
[31mwarfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. WARFARIN: [0m
[31mclinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: WARIS II â€“ Distribution of Events According to Treatment Group[0m
[31mEvent Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a [0m[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m
[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b < [0m
[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral [0m
[31mhemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as compared with aspirin. c The rate ratio is for warfarin as compared [0m
[31mwith aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products, and inhibitors and inducers of [0m
[31mCYP2C9, 1A2, or 3A4. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium or increased risks for bleeding. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m General [0m
[31mInformation Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism [0m[1;31m([0m[31mimpaired[0m
[31mhemostasis, reduced clotting factor synthesis[0m[1;31m)[0m[31m, competitive antagonism [0m[1;31m([0m[31mvitamin K[0m[1;31m)[0m[31m, and alteration of the physiologic control loop for vitamin K metabolism [0m[1;31m([0m[31mhereditary resistance[0m[1;31m)[0m[31m. Pharmacokinetic [0m
[31mmechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. WARFARIN: drug_interactions: It is important to note that some[0m
[31mdrugs may interact by more than one mechanism. More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, [0m
[31mincluding drugs intended for short-term use [0m[1;31m([0m[31me.g., antibiotics, antifungals, corticosteroids[0m[1;31m)[0m[31m [0m[1;31m[[0m[31m see Boxed Warning [0m[1;31m][0m[31m. Consult the labeling of all concurrently used drugs to obtain further information [0m
[31mabout interactions with warfarin sodium or adverse reactions pertaining to bleeding. [0m[1;31m7.2[0m[31m CYP450 Interactions CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, [0m
[31m1A2, and 3A4. The more potent warfarin S -enantiomer is metabolized by CYP2C9 while the R -enantiomer is metabolized by CYP1A2 and 3A4. WARFARIN: drug_interactions: Inhibitors of CYP2C9, 1A2, and/or [0m
[31m3A4 have the potential to increase the effect [0m[1;31m([0m[31mincrease INR[0m[1;31m)[0m[31m of warfarin by increasing the exposure of warfarin. Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect [0m[1;31m([0m[31mdecrease[0m
[31mINR[0m[1;31m)[0m[31m of warfarin by decreasing the exposure of warfarin. Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table [0m[1;31m2[0m[31m ; however, this list should not be considered all-inclusive. [0m
[31mConsult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, [0m
[31mstopping, or changing dose of concomitant medications. WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of [0m
[31mCYP450 Interactions with Warfarin Enzyme Inhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, [0m
[31msulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, [0m
[31menoxacin, famotidine, fluvoxamine WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, [0m
[31mticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, [0m
[31matazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, [0m
[31mfosamprenav WARFARIN: drug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, [0m
[31mranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, [0m
[31mnafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN:[0m
[31mdrug_interactions: Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: [0m
[31mdrug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents[0m
[31maspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, [0m
[31mketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, [0m
[31mparoxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or [0m
[31mantifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic [0m
[31mor antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, [0m
[31mwell-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with [0m
[31mbotanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals [0m
[31mmay cause bleeding events when taken alone [0m[1;31m([0m[31me.g. WARFARIN: drug_interactions: garlic and Ginkgo biloba[0m[1;31m)[0m[31m and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be[0m
[31mexpected to be additive to the anticoagulant effects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium [0m[1;31m([0m[31me.g., co-enzyme Q [0m[1;31m10[0m[31m , St. Johnâ€™s wort, ginseng[0m[1;31m)[0m[31m. Some[0m
[31mbotanicals and foods can interact with warfarin sodium through CYP450 interactions [0m[1;31m([0m[31me.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. Johnâ€™s wort[0m[1;31m)[0m[31m. The amount of vitamin K in food may affect [0m
[31mtherapy with warfarin sodium. Advise patients taking warfarin sodium to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking warfarin sodium should avoid drastic [0m
[31mchanges in dietary habits, such as eating large amounts of green leafy vegetables.         [0m
[31mSOURCE:WARFARIN label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does warfarin increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes warfarin increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes warfarin increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does warfarin increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does warfarin increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does warfarin increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes warfarin increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes warfarin increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does warfarin increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: WARFARIN: clinical_studies: [0m[1;31m14[0m[31m CLINICAL STUDIES [0m[1;31m14.1[0m[31m Atrial Fibrillation In five prospective, randomized, controlled clinical trials involving [0m[1;31m3711[0m[31m patients with non-rheumatic AF, warfarin [0m
[31msignificantly reduced the risk of systemic thromboembolism including stroke [0m[1;31m([0m[31msee Table [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m. The risk reduction ranged from [0m[1;31m60[0m[31m% to [0m[1;31m86[0m[31m% in all except one trial [0m[1;31m([0m[31mCAFA: [0m[1;31m45[0m[31m%[0m[1;31m)[0m[31m, which was stopped early due [0m
[31mto published positive results from two of these trials. The incidence of major bleeding in these trials ranged from [0m[1;31m0.6[0m[31m% to [0m[1;31m2.7[0m[31m% [0m[1;31m([0m[31msee Table [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m. Table [0m[1;31m4[0m[31m: Clinical Studies of Warfarin in Non-Rheumatic [0m
[31mAF Patients * N Thromboembolism % Major Bleeding Study Warfarin-Treated Patients Control Patients PT Ratio INR % Risk Reduction p -value Warfarin-Treated Patients Control Patients AFASAK [0m[1;31m335[0m[31m [0m[1;31m336[0m[31m [0m[1;31m1.5[0m[31m [0m
[31mto [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m. WARFARIN: clinical_studies: [0m[1;31m8[0m[31m to [0m[1;31m4.2[0m[31m [0m[1;31m60[0m[31m [0m[1;31m0.027[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m SPAF [0m[1;31m210[0m[31m [0m[1;31m211[0m[31m [0m[1;31m1.3[0m[31m to [0m[1;31m1.8[0m[31m [0m[1;31m2[0m[31m to [0m[1;31m4.5[0m[31m [0m[1;31m67[0m[31m [0m[1;31m0.01[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m1.9[0m[31m BAATAF [0m[1;31m212[0m[31m [0m[1;31m208[0m[31m [0m[1;31m1.2[0m[31m to [0m[1;31m1.5[0m[31m [0m[1;31m1.5[0m[31m to [0m[1;31m2.7[0m[31m [0m[1;31m86[0m[31m < [0m[1;31m0.05[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m0.5[0m[31m CAFA [0m[1;31m187[0m[31m [0m[1;31m191[0m[31m [0m[1;31m1.3[0m[31m to [0m[1;31m1.6[0m[31m [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m [0m[1;31m45[0m[31m [0m
[1;31m0.25[0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m0.5[0m[31m SPINAF [0m[1;31m260[0m[31m [0m[1;31m265[0m[31m [0m[1;31m1.2[0m[31m to [0m[1;31m1.5[0m[31m [0m[1;31m1.4[0m[31m to [0m[1;31m2.8[0m[31m [0m[1;31m79[0m[31m [0m[1;31m0.001[0m[31m [0m[1;31m2.3[0m[31m [0m[1;31m1.5[0m[31m * All study results of warfarin vs. WARFARIN: clinical_studies: control are based on intention-to-treat analysis and include ischemic[0m
[31mstroke and systemic thromboembolism, excluding hemorrhagic stroke and transient ischemic attacks. Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with [0m
[31mwarfarin sodium [0m[31m . [0m[1;31m14.2[0m[31m Mechanical and Bioprosthetic Heart Valves In a prospective, randomized, open-label, positive-controlled study in [0m[1;31m254[0m[31m patients with mechanical prosthetic heart valves, the [0m
[31mthromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients [0m[1;31m([0m[31mp < [0m[1;31m0.005[0m[1;31m)[0m[31m and [0m
[31mpentoxifylline/aspirin-treated patients [0m[1;31m([0m[31mp < [0m[1;31m0.05[0m[1;31m)[0m[31m. The results of this study are presented in Table [0m[1;31m5[0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in the lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction [0m
[31mWARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with warfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint [0m
[31mwas a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was [0m[1;31m37[0m[31m months. The results for each endpoint [0m
[31mseparately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis of Separate Events % Risk Warfarin Placebo Reduction Event[0m
[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m
[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m
[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial infarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, [0m
[31mRe-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with warfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or [0m
[31mwarfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. WARFARIN: [0m
[31mclinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: WARIS II â€“ Distribution of Events According to Treatment Group[0m
[31mEvent Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a [0m[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m
[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b < [0m
[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral [0m
[31mhemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as compared with aspirin. c The rate ratio is for warfarin as compared [0m
[31mwith aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: dosage_and_administration: [0m[1;31m2[0m[31m DOSAGE AND ADMINISTRATION Individualize dosing regimen for each patient, and adjust based on INR response. [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m , [0m[1;31m2.2[0m[31m [0m[1;31m)[0m[31m Knowledge of genotype can [0m
[31minform initial dose selection. [0m[1;31m([0m[31m [0m[1;31m2.3[0m[31m [0m[1;31m)[0m[31m Monitoring: Obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determinations every [0m[1;31m1[0m[31m to [0m[1;31m4[0m[31m weeks. [0m[1;31m([0m[31m [0m[1;31m2.4[0m
[1;31m)[0m[31m Review conversion instructions from other anticoagulants. [0m[1;31m([0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m)[0m[31m [0m[1;31m2.1[0m[31m Individualized Dosing The dosage and administration of warfarin sodium tablets must be individualized for each patient according[0m
[31mto the patientâ€™s International Normalized Ratio [0m[1;31m([0m[31mINR[0m[1;31m)[0m[31m response to the drug. Adjust the dose based on the patientâ€™s INR and the condition being treated. Consult the latest evidence-based clinical [0m
[31mpractice guidelines regarding the duration and intensity of anticoagulation for the indicated conditions. [0m[1;31m2[0m[31m. WARFARIN: dosage_and_administration: [0m[1;31m2[0m[31m Recommended Target INR Ranges and Durations for [0m
[31mIndividual Indications An INR of greater than [0m[1;31m4[0m[31m appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Venous Thromboembolism [0m
[1;31m([0m[31mincluding deep venous thrombosis [0m[1;31m[[0m[31mDVT[0m[1;31m][0m[31m and PE[0m[1;31m)[0m[31m Adjust the warfarin dose to maintain a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mINR range, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m for all treatment durations. The duration of treatment is based on the [0m
[31mindication as follows: For patients with a DVT or PE secondary to a transient [0m[1;31m([0m[31mreversible[0m[1;31m)[0m[31m risk factor, treatment with warfarin for [0m[1;31m3[0m[31m months is recommended. For patients with an unprovoked DVT or PE, [0m
[31mtreatment with warfarin is recommended for at least [0m[1;31m3[0m[31m months. After [0m[1;31m3[0m[31m months of therapy, evaluate the risk-benefit ratio of long-term treatment for the individual patient. WARFARIN: [0m
[31mdosage_and_administration: For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended. For a patient receiving long-term anticoagulant treatment, [0m
[31mperiodically reassess the risk-benefit ratio of continuing such treatment in the individual patient. Atrial Fibrillation In patients with non-valvular AF, anticoagulate with warfarin to target INR of [0m
[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m. In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke [0m[1;31m([0m[31mi.e., having any of the following features: prior ischemic stroke, transient ischemic[0m
[31mattack, or systemic embolism, or [0m[1;31m2[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of [0m
[31mhypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. WARFARIN: dosage_and_administration: In patients with non-valvular AF that is persistent or paroxysmal and [0m
[31mat an intermediate risk of ischemic stroke [0m[1;31m([0m[31mi.e., having [0m[1;31m1[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or severely impaired left ventricular systolic function and/or heart [0m
[31mfailure, history of hypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. For patients with AF and mitral stenosis, long-term anticoagulation with warfarin is [0m
[31mrecommended. For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR may be increased and aspirin added depending on valve type and [0m
[31mposition, and on patient factors. WARFARIN: dosage_and_administration: Mechanical and Bioprosthetic Heart Valves For patients with a bileaflet mechanical valve or a Medtronic Hall [0m[1;31m([0m[31mMinneapolis, MN[0m[1;31m)[0m[31m [0m
[31mtilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement, therapy with warfarin to a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m is recommended. For patients with [0m
[31mtilting disk valves and bileaflet mechanical valves in the mitral position, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m to [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with caged ball or caged disk [0m
[31mvalves, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m to [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with a bioprosthetic valve in the mitral position, therapy with warfarin to a target INR of [0m[1;31m2[0m[31m.      [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: While warfarin sodium is contraindicated during pregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with [0m
[31mmechanical heart valves at high risk of thromboembolism. In those individual situations, the decision to initiate or continue warfarin sodium should be reviewed with the patient, taking into [0m
[31mconsideration the specific risks and benefits pertaining to the individual patientâ€™s medical situation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes[0m
[31ma recognized pattern of major congenital malformations [0m[1;31m([0m[31mwarfarin embryopathy and fetotoxicity[0m[1;31m)[0m[31m, fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug [0m
[31mis used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [0m[31m . [0m[1;31m5[0m[31m. WARFARIN: warnings_and_cautions: [0m[1;31m8[0m[31m Other [0m
[31mClinical Settings with Increased Risks In the following clinical settings, the risks of warfarin sodium therapy may be increased: Moderate to severe hepatic impairment Infectious diseases or [0m
[31mdisturbances of intestinal flora [0m[1;31m([0m[31me.g., sprue, antibiotic therapy[0m[1;31m)[0m[31m Use of an indwelling catheter Severe to moderate hypertension Deficiency in protein C-mediated anticoagulant response: Warfarin [0m
[31msodium reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with [0m
[31mtissue necrosis following warfarin administration. Concomitant anticoagulation therapy with heparin for [0m[1;31m5[0m[31m to [0m[1;31m7[0m[31m days during initiation of therapy with warfarin sodium may minimize the incidence of [0m
[31mtissue necrosis in these patients. WARFARIN: warnings_and_cautions: Eye surgery: In cataract surgery, warfarin sodium use was associated with a significant increase in minor complications of sharp [0m
[31mneedle and local anesthesia block but not associated with potentially sight-threatening operative hemorrhagic complications. As warfarin sodium cessation or reduction may lead to serious [0m
[31mthromboembolic complications, the decision to discontinue warfarin sodium before a relatively less invasive and complex eye surgery, such as lens surgery, should be based upon the risks of [0m
[31manticoagulant therapy weighed against the benefits. Polycythemia vera Vasculitis Diabetes mellitus [0m[1;31m5.9[0m[31m Endogenous Factors Affecting INR The following factors may be responsible for increased INR [0m
[31mresponse: diarrhea, hepatic disorders, poor nutritional state, steatorrhea, or vitamin K deficiency. The following factors may be responsible for decreased INR response: increased vitamin K intake or [0m
[31mhereditary warfarin resistance.         [0m
[31mSOURCE:WARFARIN label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I attempted to retrieve information from FDAHandler regarding the effect of warfarin on the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"FDAHandler consistently responded with 'DO-NOT-KNOW,' indicating that the FDA label for warfarin does not contain information about its impact on the risk of hip fracture."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I attempted to retrieve information from FDAHandler regarding the effect of warfarin on the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"FDAHandler consistently responded with 'DO-NOT-KNOW,' indicating that the FDA label for warfarin does not contain information about its impact on the risk of hip fracture."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I attempted to retrieve information from FDAHandler regarding the effect of warfarin on the risk of hip fracture.[0m
[1;31m2[0m[31m. FDAHandler consistently responded with [0m[31m'DO-NOT-KNOW,'[0m[31m indicating that the FDA label for warfarin does not contain information about its impact on the risk of hip fracture.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for warfarin does not contain information about its impact on the risk of hip fracture, as indicated by the consistent [0m[32m"DO-NOT-KNOW"[0m[32m responses from FDAHandler. Therefore, I cannot [0m
[32mprovide a definitive answer on whether warfarin increases or decreases the risk of hip fracture.[0m
